Logiscreen

BridgeBio Pharma Inc

$67.61
Market Cap 13.11B
ROE 35.7%
Gross Margin 94.9%
Debt/Equity -1.1
Current Ratio 1.5
Revenue QoQ 66.8%
EPS QoQ -0.0%
F-Score 3

About

BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-18.09
vs median 33.61
P/B
-5.73
vs median 2.16
ROE
0.36
vs median 0.09

Lower quality - review fundamentals carefully

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics